C4T news

Latest 2 stories · newest Sep 25, 2026

C4T

C4 Therapeutics Presents Biomarker Data from New Myeloma Trials

C4 Therapeutics presented new biomarker reinforcing the immunomodulatory activity of cemsidomide in combination therapies at the 23rd IMS Annual Meeting, with data expected in Mid-2027.

Regulatory Sep 25, 2026 sentiment 0.00 SEC filing ↗

C4T

C4 Therapeutics amends stock option plan to allow 5% annual increase

C4 Therapeutics approved amendment No. 2 to its 2020 plan, authorizing annual share increases of up to 5%. This corporate governance update aims to provide long-term flexibility for employee compensation and retention.

Regulatory Jun 24, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same C4T feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/C4T/newsSTART FREE